Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-κB ligand: The tromso study

Osteoporosis International

Volumn 21, Issue 6, 2010, Pages 931-938

  Jorgensen L ^a,b   Vik, A ^a   Emaus, N ^a   Brox, J ^a,b   Hansen, J B ^a   Mathiesen, E ^a,b   Vestergaard, P ^c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone loss; Bone mineral density; Epidemiology; Nuclear factor b ligand; Osteoprotegerin

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; VITAMIN D;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE ATROPHY; BONE DENSITY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; MALE; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; AGING; BONE DENSITY; BONE DISEASES, METABOLIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; RANK LIGAND; SEX FACTORS;

EID: 77954565075     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1035-6     Document Type: Article

References (34)

1. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050-5055
2. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-1508
3. Vega D, Maalouf NM, Sakhaee K (2007) Clinical review: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514-4521
4. Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL (2005) Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 36:727-735
5. Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
6. Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK (2005) The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol 62:349-353
7. Indridason OS, Franzson L, Sigurdsson G (2005) Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 16:417-423
8. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL (2002) Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394-399
9. Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM (2008) Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause 15:357-362
10. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32:681-686
11. Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Z, Sun LH, Xu MY, Chen JL (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 76:1-6
12. Oh KW, Rhee EJ, Lee WY, Kim SW, Oh ES, Baek KH, Kang MI, Choi MG, Yoo HJ, Park SW (2004) The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol 61:244-249
13. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R (2002) Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470-4475 (Pubitemid 35247027)
14. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162-3165
15. Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K, Irahara M (2008) Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in postmenopausal women. J Endocrinol Investig 31:163-168
16. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111:2461-2468
17. Jørgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB (2004) Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab 22:132-138
18. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527
19. Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol 62:92-98
20. Samelson EJ, Broe KE, Demissie S, Beck TJ, Karasik D, Kathiresan S, Kiel DP (2008) Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab 93:1789-1795
21. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios LJ, Escobar-Jimenez F, Munoz-Torres M (2005) The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 16:1368-1374
22. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of nontraumatic fracture. JAMA 291:1108-1113 (Pubitemid 38541688)
23. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 156:555-562
24. Jørgensen L, Joakimsen O, Mathiesen EB, Ahmed L, Berntsen GK, Fønnebø V, Joakimsen R, Njølstad I, Schirmer H, Jacobsen BK (2006) Carotid plaque echogenicity and risk of nonvertebral fractures in women: a longitudinal population-based study. Calcif Tissue Int 79:207-213
25. Berntsen GK, Tollan A, Magnus JH, Søgaard AJ, Ringberg T, Fønnebø V (1999) The Tromsø Study: artifacts in forearm bone densitometry-prevalence and effect. Osteoporos Int 10:425-432
26. Berntsen GK, Fønnebø V, Tollan A, Søgaard AJ, Joakimsen RM, Magnus JH (2000) The Tromsø Study: determinants of precision in bone densitometry. J Clin Epidemiol 53:1104-1112
27. Emaus N, Berntsen GK, Joakimsen R, Fønnebø V (2005) Bone mineral density measures in longitudinal studies: the choice of phantom is crucial for quality assessment. The Tromsø Study, a population-based study. Osteoporos Int 16:1597-1603
28. Ueland T, Brixen K, Mosekilde L, Mosekilde L, Flyvbjerg A, Bollerslev J (2003) Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP) -3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab 88:1014-1018
29. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
30. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
31. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
32. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474
33. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Gwyneth V, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
34. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176